Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro

Cell Biology International

Volumn 38, Issue 2, 2014, Pages 187-197

  Bryan, Jeffrey N ^a,b   Kumar, Senthil R ^a,b   Jia, Fang ^a,b   Balkin, Ethan R ^a,c   Lewis, Michael R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Demethylation; Lymphoma; Radiopharmaceuticals; Radiosensitivity; Somatostatin analogue

Indexed keywords

(177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; CYTIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; OCTREOTIDE; ORGANOMETALLIC COMPOUND; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMORADIOTHERAPY; DRUG EFFECTS; HUMAN; NEOPLASMS; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CYTIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; HUMANS; NEOPLASMS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS;

EID: 84895902929     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1002/cbin.10215     Document Type: Article

References (35)

1. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, Nephew KP (2005) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4: 1505-14.
2. Balkin ER, Jia F, Miller WH, Lewis MR (2011) In vitro evaluation of targeted antisense 177Lu radiotherapy. Anticancer Res 31: 3143-9.
3. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409.
4. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6: 151-8.
5. Cheson BD (2005) The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19: 309-22.
6. Choi JH, Li Y, Guo J, Pei L, Rauch TA, Kramer RS, Macmil SL, Wiley GB, Bennett LB, Schnabel JL, Taylor KH, Kim S, Xu D, Sreekumar A, Pfeifer GP, Roe BA, Caldwell CW, Bhalla KN, Shi H (2010) Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS ONE 5: e13020.
7. deJong M, Breeman WA, Valkema R, Bernard BF, Krenning EP (2005) Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 (Suppl 1), 13S-7S.
8. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 11: 4571-9.
9. Egger G, Aparicio AM, Escobar SG, Jones PA (2007) Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-20-deoxycytidine treatment. Cancer Res 67: 346-53.
10. Gyurkocza B, Rezvani A, Storb RF (2010) Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 3: 285-99.
11. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, Lyubimov AV, Chen YF, D'Argenio DZ, Egorin MJ (2005) Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11: 3862-8.
12. Jia F, Figueroa SD, Hunter CJ, Gallazzi F, Meyer AE, Lever SZ, Hannink M, Hoffman TJ, Lewis MR (2006) Molecular imaging of bcl-2 expression in chronic lymphocytic leukemia using 111In-labeled PNA-peptide conjugates. J Nucl Med 47: 94P.
13. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-66.
14. Kelly WK, Richon VM, O'Connor O, Curley T, Gregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-88.
15. Kim HJ, Kim JH, Chie EK, Young PD, Kim IA, Kim IH (2012) DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 7: 39.
16. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de JM, Srinivasan A, Erion JL, Krenning EP (2003) Treatment of patients with gastroentero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging 30: 417-22.
17. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23: 2754-62.
18. Lattuada D, Casnici C, Crotta K, Mastrotto C, Franco P, Schmid HA, Marelli O (2007) Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol 182: 153-9.
19. LeBlanc AK, LaDue TA, Turrel JM, Klein MK (2004) Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 45: 466-70.
20. Lewis JS, Laforest R, Lewis MR, Anderson CJ (2000) Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biother Radiopharm 15: 593-604.
21. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12: 5570-77.
22. Macklis RM, Beresford BA, Humm JL (1994) Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy. Cancer 73: 966-73.
23. Miller WH, Hartmann-Siantar C, Fisher D, Descalle MA, Daly T, Lehmann J, Lewis MR, Hoffman T, Smith J, Situ PD, VolkertWA (2005) Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm 20: 436-49.
24. Mohsin H, Sivaguru G, Jia F, Bryan JN, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Theodore LJ, Axworthy DB, Jurisson SS, Lewis MR (2005) Comparison of pretarget and conventional CC49 radioimmunotherapy using 149Pm, 166Ho and 177Lu. J Labelled Cpd Radiopharm 48: S21.
25. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K (2005) Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 19: 355-65.
26. Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, DuffD, Shi H, Davis JW, Hooshmand SI, Chitma-Matsiga R, Caldwell CW (2006) Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 20: 1855-62.
27. Rodel S, Engert A, Diehl V, Reiser M (2005) Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leuk Lymphoma 46: 1729-34.
28. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R, Volkert WA, Hoffman TJ (2003) Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH) 3. Cancer Res 63: 4082-8.
29. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Cambrin G, Thunberg U, Nilsson K, Caligaris-Cappio F (1999) MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 23: 127-36.
30. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-800.
31. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36: 147-56.
32. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ (2006) Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47: 1599-606.
33. Weiner RE, Thakur ML (2005) Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 19: 145-63.
34. Williams LE, Johnson JL, Hauck ML, Ruslander DM, Price GS, Thrall DE (2004) Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 18: 703-9.
35. Wiseman GA, White CA, Stabin M, Dunn WL, ErwinW, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-Lopez AJ (2000) Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27: 766-77.